{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/giant-cell-arteritis/management/management/","result":{"pageContext":{"chapter":{"id":"ecd920ae-cdc1-5314-ba21-3936f06fc825","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 83988067-5cee-422a-a7f2-9342d93edd59 --><h2>Scenario: Management of giant cell arteritis</h2><!-- end field 83988067-5cee-422a-a7f2-9342d93edd59 -->","summary":"Covers the initial and ongoing management of giant cell arteritis, including when to refer.","htmlStringContent":"<!-- begin item 661a1397-59c8-49c6-8fa9-7ff1f68644b1 --><!-- begin field 5a7e5f52-9f67-4919-8ccc-acbc0159537a --><p>From age 40 years onwards.</p><!-- end field 5a7e5f52-9f67-4919-8ccc-acbc0159537a --><!-- end item 661a1397-59c8-49c6-8fa9-7ff1f68644b1 -->","topic":{"id":"7eefe727-da7a-5ac5-a30a-dadcb4a4de90","topicId":"922f2e2a-90b2-4d8e-8df9-97f686e2dd9c","topicName":"Giant cell arteritis","slug":"giant-cell-arteritis","lastRevised":"Last revised in September 2020","chapters":[{"id":"28844a63-ce71-58a4-ac10-fb8f990a2ace","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9ffc44fb-e6ab-5564-afaf-41f6ec23ae59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d9822672-70ac-5f30-a37c-163c926d69f9","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8b641dad-e801-5f07-a15f-837c9e204ae5","slug":"changes","fullItemName":"Changes"},{"id":"b6663d8f-4d43-5493-b6ea-21be0eeae0f0","slug":"update","fullItemName":"Update"}]},{"id":"fbf9fbe8-db19-571e-9da9-58c8a33c3a25","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4a198ad6-17e2-5c80-a074-90f34f9ef1b7","slug":"goals","fullItemName":"Goals"},{"id":"a77ffdda-deba-58f0-9fec-65219eeb836f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0979f67-3177-527b-add9-89f384b45f07","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c79d9855-b433-5fba-b27d-0999158ea93d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"941fce5c-cd66-5a8b-94ed-bcdf176a7c54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e4b575e0-3a70-5c29-afb2-b56f7ba46307","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a1c8cdf0-c725-5fb8-889a-3531e77f7aeb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ea4258e9-d463-5d81-ac84-d12cda80042f","slug":"definition","fullItemName":"Definition"},{"id":"cfe98d94-f2b6-58e5-828a-449fb49d3b2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bd2e22a0-2e56-5c05-9b4e-9953cc1765f9","slug":"complications","fullItemName":"Complications"},{"id":"0c5a3725-06fd-5f2f-8aae-4f12da09ec7d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4ce95be1-65d5-5341-a648-8f3418d06670","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c5043d32-5bcd-5396-a271-5864a6d96e74","slug":"suspecting-giant-cell-arteritis","fullItemName":"Suspecting giant cell arteritis"},{"id":"e8c3752d-f9fb-5624-a000-60653edb83ac","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"95e6b3e6-ba05-5b56-8edc-9571fe816995","fullItemName":"Management","slug":"management","subChapters":[{"id":"ecd920ae-cdc1-5314-ba21-3936f06fc825","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c0f0c8dc-11b9-52b8-ba73-a9c6e75e1731","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4e1c5dd9-0908-56f2-91a3-604ea1f9e73d","slug":"oral-prednisolone","fullItemName":"Oral prednisolone"}]},{"id":"5a8fb527-3c07-5253-86eb-d10fc0d5b656","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ff1b1a4d-96ab-5f26-82ea-b4b059ac602f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"627bf4b4-8b65-59ac-8e48-1f7ac20afa3c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"403ae553-2865-56af-9e95-a012c674b4de","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17c8d522-4e76-5f45-aa32-83ed694272f1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bb85fa5d-a667-5361-b411-a3837f26bdc3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1f292226-0f24-56c9-983b-c8fa1738c13f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e1a018ae-4d22-516e-8a99-d688c0d3dda6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"95e6b3e6-ba05-5b56-8edc-9571fe816995","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"720ac3ea-f0d9-5329-a84b-6b046a458b1e","slug":"initial-management","fullItemName":"Initial management","depth":3,"htmlHeader":"<!-- begin field b066c919-308b-493c-939e-a960ec397f99 --><h3>What initial management is required for someone with suspected giant cell arteritis?</h3><!-- end field b066c919-308b-493c-939e-a960ec397f99 -->","summary":null,"htmlStringContent":"<!-- begin item f9dab060-f0ed-4ac4-a959-4efdabe22375 --><!-- begin field b506d486-2440-4523-a00e-b663b89817df --><ul><li class=\"MsoNormal\"><strong>Giant cell arteritis (GCA) is a medical emergency.</strong><ul><li class=\"MsoNormal\">Early treatment with effective doses of glucocorticoids may prevent serious complications such as vision loss.</li></ul></li><li class=\"MsoNormal\"><strong>If there is new visual loss (transient or permanent) or double vision:</strong><ul><li class=\"MsoNormal\">Arrange an urgent (same day) assessment by an ophthalmologist.</li><li class=\"MsoNormal\">Depending on the clinical situation, the specialist may advise one-off high dose corticosteroid treatment in primary care while the person awaits transfer to ophthalmology.</li><li class=\"MsoNormal\">Acute or intermittent visual loss due to GCA is usually treated with intravenous glucocorticoid therapy; if this is not possible, 60–100 mg oral prednisolone may be given for up to 3 consecutive days.</li></ul></li><li class=\"MsoNormal\"><strong>For all other people with suspected GCA:</strong><ul><li class=\"MsoNormal\"><strong>Urgently discuss with a specialist and refer using a fast track local GCA pathway.</strong><ul><li class=\"MsoNormal\">Specialist assessment (usually a rheumatologist) should be on the same working day if possible, and in all cases within 3 working days.</li></ul></li><li class=\"MsoNormal\"><strong>Suspected GCA should be immediately treated with glucocorticoids.</strong><ul><li class=\"MsoNormal\">Discuss the need for initiation of glucocorticoid treatment in primary care with the specialist — the standard initial dose for active GCA without visual symptoms is 40–60 mg oral prednisolone per day.</li></ul></li><li class=\"MsoNormal\"><strong>Consider arranging the following blood tests</strong> to support diagnosis unless there is evidence of critical ischaemia (such as visual loss or diplopia) or no immediate access to phlebotomy but do not delay referral while waiting for results:<ul><li class=\"MsoNormal\">Full blood count, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR).</li><li class=\"MsoNormal\">For additional information on blood tests, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/giant-cell-arteritis/management/management/#investigations-in-primary-care\">Investigations in primary care</a>.</li></ul></li><li class=\"MsoNormal\"><strong>Diagnosis will be confirmed in secondary care with investigations such as ultrasound and biopsy.</strong><ul><li class=\"MsoNormal\">Follow up will usually be arranged in secondary care but may be via a shared care model. Regular review is needed to assess treatment response, risk of adverse effects, and identify relapses.</li><li class=\"MsoNormal\">Response of symptoms to corticosteroids is usually rapid — if response to prednisolone is poor, an alternative diagnosis should be considered.</li><li class=\"MsoNormal\">Corticosteroid dose is normally reduced very slowly over several months. Treatment is often required for 1–2 years, but people may require low doses for several years.</li><li class=\"MsoNormal\">For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/giant-cell-arteritis/management/management/#ongoing-management\">Follow up</a>.</li></ul></li></ul></li><li class=\"MsoNormal\"><strong>Ensure the person understands the importance of attending for regular follow up and advise them to:</strong><ul><li class=\"MsoNormal\">Seek immediate (same day) medical attention if they develop any visual disturbances (such as visual loss, double vision, or visual field defects).</li><li class=\"MsoNormal\">Seek prompt medical attention if non-visual symptoms of GCA (for example return of headache or jaw claudication) develop.</li></ul></li><li class=\"MsoNormal\"><strong>Signpost to sources of information about GCA and its treatment such as:</strong><ul><li class=\"MsoNormal\">Arthritis Research UK — <a href=\"https://www.versusarthritis.org/media/1319/giant-cell-arteritis-information-booklet.pdf\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"eefd1497-58b7-475b-bb93-ac4500cfd73c\">Giant cell arteritis (temporal arteritis)</a>.</li><li class=\"MsoNormal\">NHS — <a href=\"https://www.nhs.uk/conditions/temporal-arteritis\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"dd425805-66ed-4554-a3bc-ac4500cfd780\">Temporal arteritis</a>.</li><li class=\"MsoNormal\">RNIB — <a href=\"https://www.rnib.org.uk/eye-health/eye-conditions/giant-cell-arteritis\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"e664b9d8-097a-4844-8ce3-ac4500cfd7a2\">Giant cell arteritis</a>.</li></ul></li></ul><!-- end field b506d486-2440-4523-a00e-b663b89817df --><!-- end item f9dab060-f0ed-4ac4-a959-4efdabe22375 -->","subChapters":[{"id":"c1e9e373-4188-5b3f-a53c-1fac24c38e1b","slug":"basis-for-recommendation-bb3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 87574c2c-23d3-4bb4-99a1-86acc8c88719 --><h4>Basis for recommendation</h4><!-- end field 87574c2c-23d3-4bb4-99a1-86acc8c88719 -->","summary":null,"htmlStringContent":"<!-- begin item bb37aaf9-81f3-440d-8fad-6ac61c2650be --><!-- begin field 3f8a39f8-6121-4dc4-9111-c5d56443b0b1 --><p class=\"MsoNormal\">These recommendations are largely based on <em>The British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>], the European clinical guidelines <em>Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Turesson, 2019</a>], <em>2018 Update of the EULAR recommendations for the management of large vessel vasculitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>], the <em>European Headache Federation recommendations for neurologists managing giant cell arteritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mollan, 2020</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Prior, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Buttgereit, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>].</p><h5 class=\"MsoNormal\">Giant cell arteritis (GCA) is a medical emergency</h5><ul><li class=\"MsoNormal\">Expert opinion in clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Turesson, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mollan, 2020</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Prior, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>] is that suspected GCA is a medical emergency because of the risk of sudden irreversible sight loss and other serious complications.<ul><li class=\"MsoNormal\">Prompt diagnostic evaluation by a clinician with appropriate specialist expertise (usually a rheumatologist) and early treatment with effective doses of glucocorticoids is required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Turesson, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mollan, 2020</a>].</li><li class=\"MsoNormal\">The statement that people with suspected GCA should be urgently referred and seen by a specialist, ideally on the same working day and in all cases within 3 working days, is taken from the British Society for Rheumatology (BSR) guideline — undiscerning use of high dose glucocorticoids may mask other diseases and can complicate the diagnostic workup [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li><li class=\"MsoNormal\">Lower rates of GCA-related sight loss have been reported from centres with fast track referral pathways (where initial diagnostic evaluation and treatment of people with suspected GCA occurs within 24 hours of referral) compared with conventional care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li></ul></li><li class=\"MsoNormal\">Same day ophthalmological evaluation is essential where there is new visual loss (transient or permanent) or double vision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mollan, 2020</a>].<ul><li class=\"MsoNormal\">The recommendation that people presenting with a history of new visual loss (transient or permanent) or double vision should be evaluated as soon as possible on the same calendar day by an ophthalmologist is taken from the British Society for Rheumatology (BSR) clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li><li class=\"MsoNormal\">Delaying therapy when visual loss is present is the strongest risk factor for permanent blindness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>].</li></ul></li></ul><h5 class=\"MsoNormal\">Glucocorticoid treatment</h5><ul><li class=\"MsoNormal\">The BSR recommends that if GCA is strongly suspected it should be treated immediately with high dose corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].<ul><li class=\"MsoNormal\">On suspicion of GCA, primary care providers should initiate glucocorticoids alongside an urgent referral to the local GCA pathway — most GCA-associated visual loss occurs before or shortly after glucocorticoid treatment is initiated, highlighting the importance of immediate treatment when the disease is strongly suspected [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li><li class=\"MsoNormal\">The risk of toxicity caused by short-term glucocorticoid treatment commenced in patients with initial strong suspicion of GCA but then diagnosed with an alternative condition is acceptably low, as long as a full diagnostic evaluation is performed promptly and it is acknowledged that suspicion of GCA is not the same as a diagnosis of GCA [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li></ul></li><li class=\"MsoNormal\">BSR make a conditional recommendation that the standard initial dose for GCA without visual symptoms is 40–60 mg oral prednisolone per day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].<ul><li class=\"MsoNormal\">No clinical trials have been conducted in people with acute ocular ischaemia — BSR conditionally recommend that people with acute or intermittent visual loss may initially be given 500–1000 mg intravenous methylprednisolone daily for up to 3 consecutive days before commencing oral prednisolone therapy and that where intravenous therapy is not immediately possible, this should not delay initiation of oral prednisolone (60–100 mg daily for up to 3 consecutive days).</li><li class=\"MsoNormal\">CKS advises that one-off dose may be given in primary care as same day referral to ophthalmology is required for people with visual symptoms.</li></ul></li></ul><h5 class=\"MsoNormal\">Investigations in primary care</h5><ul><li class=\"MsoNormal\">The BSR recommend that when starting glucocorticoids for suspected GCA, diagnostically relevant symptoms and signs should be documented, and blood taken for full blood count, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) before or immediately after commencing high dose glucocorticoids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].<ul><li class=\"MsoNormal\">ESR, CRP, or both are typically elevated in more than 95% of GCA cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Buttgereit, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>] but can be normal in between 1 and 10% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mollan, 2020</a>].</li><li class=\"MsoNormal\">Other blood test abnormalities that can be observed with a diagnosis of GCA include normochromic normocytic anaemia, elevated platelet count, and cholestatic liver enzyme patterns, as a result of arterial vasculitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mollan, 2020</a>].</li></ul></li><li class=\"MsoNormal\">If GCA is strongly suspected, referral and the first dose of glucocorticoid can be given without waiting for laboratory results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li></ul><h5 class=\"MsoNormal\">Secondary care diagnosis</h5><ul><li class=\"MsoNormal\">Urgent assessment and case by case decisions on appropriate treatment should be made by a specialist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Turesson, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li><li class=\"MsoNormal\">The BSR [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>] and EULAR [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>] recommend that all people with suspected GCA should have at least one confirmatory diagnostic test (strong recommendation):  <ul><li class=\"MsoNormal\">Temporal and axillary artery ultrasound, or</li><li class=\"MsoNormal\">Temporal artery biopsy.</li></ul></li></ul><h5 class=\"MsoNormal\">Advice</h5><ul><li>This is a pragmatic recommendation and reflects the need to prevent ocular complications and corticosteroid adverse effects.</li></ul><!-- end field 3f8a39f8-6121-4dc4-9111-c5d56443b0b1 --><!-- end item bb37aaf9-81f3-440d-8fad-6ac61c2650be -->","subChapters":[]},{"id":"dd7913ba-4940-5ab7-8684-44275245349e","slug":"investigations-in-primary-care","fullItemName":"Investigations in primary care","depth":4,"htmlHeader":"<!-- begin field 8d2db7ea-6b90-4283-9b49-ac4400b4a643 --><h4>What investigations should I consider in primary care?</h4><!-- end field 8d2db7ea-6b90-4283-9b49-ac4400b4a643 -->","summary":null,"htmlStringContent":"<!-- begin item adbc07af-2c62-4871-b6c7-418437fa31f9 --><!-- begin field 0ea3ccae-179c-4f26-912e-ac4400b4a643 --><ul><li class=\"MsoNormal\"><strong>If giant cell arteritis (GCA) is suspected do not delay referral while waiting for results</strong> — discuss with a specialist if unsure.</li><li><strong>The following tests may be helpful in establishing a diagnosis of GCA</strong> but definitive diagnosis relies on further assessment and investigation (such as imaging and biopsy) in secondary care.<ul><li>Full blood count — normochromic normocytic anaemia and an elevated platelet count are common.</li><li>C-reactive protein (CRP) — the CRP level is typically elevated.</li><li>Erythrocyte sedimentation rate (ESR) — the ESR is often greater than 50 mm/hour. However, the ESR may be normal at presentation and even during a flare of disease activity.</li></ul></li><li><strong>Depending on the clinical situation, other investigations may be indicated</strong> to exclude alternative diagnoses or identify increased risk of glucocorticoid-related adverse effects for example:<ul><li>Baseline urea and electrolytes, HbA1c, calcium and liver function tests.</li><li>Serum protein electrophoresis and urine Bence–Jones protein/serum-free light chains if ESR is elevated out of proportion to CRP.</li><li>Screening tests for risk of serious infection (such as urine dipstick, chest X-ray, and tests for latent tuberculosis).</li><li>Screening tests for osteoporosis risk (such as TSH, vitamin D, bone density test, DEXA).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Buttgereit, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">NICE, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mollan, 2020</a>]</p><!-- end field 0ea3ccae-179c-4f26-912e-ac4400b4a643 --><!-- end item adbc07af-2c62-4871-b6c7-418437fa31f9 -->","subChapters":[]}]},{"id":"e3c84aa6-2036-53ff-9a80-671c138c370b","slug":"ongoing-management","fullItemName":"Ongoing management","depth":3,"htmlHeader":"<!-- begin field 36a50d88-1d88-43c7-9d97-4b14a6afcd7c --><h3>What ongoing management is required for someone with confirmed giant cell arteritis?</h3><!-- end field 36a50d88-1d88-43c7-9d97-4b14a6afcd7c -->","summary":null,"htmlStringContent":"<!-- begin item 94b46bfa-8ecd-4364-a68b-acdaa068a719 --><!-- begin field aae8ce3c-0e63-49e2-905b-e6a7c04613e9 --><p><strong>Once a diagnosis of giant cell arteritis (GCA) has been confirmed by a specialist:</strong></p><ul><li><strong>Follow up will usually be arranged in secondary care but may be provided using a shared care model.</strong><ul><li>Treatment duration is usually 1–2 years, but some people may require low doses of corticosteroids for several further years.</li><li>Assessment of prognostic factors and comorbidities relevant to treatment (such as risk of infection, diabetes, hypertension, glaucoma, peptic ulcer, and bone fracture risk) and consideration of preventative measures (such as bone and/or gastrointestinal protection) should take place soon after diagnosis.</li><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids – oral</a> and <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>.</li><li>The person’s specialist may consider treatment with either methotrexate or tocilizumab in combination with tapered glucocorticoid treatment if risk of glucocorticoid toxicity is high.</li></ul></li><li><strong>The person should be reviewed by a clinician with appropriate expertise:</strong><ul><li>Every 2–8 weeks during the first 6 months of diagnosis — close monitoring of blood pressure and blood glucose is particularly important after initiation of glucocorticoids.</li><li>Every 12 weeks during the second 6 months.</li><li>Every 12–24 weeks during the second year.</li><li>At any point, if relapse occurs.</li><li>When glucocorticoid therapy is tapered and discontinued.</li></ul></li><li><strong>Every review should include:</strong><ul><li>A full history for symptoms of disease control, relapse, and complications.</li><li>A targeted examination.</li><li>Blood monitoring including full blood count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).</li><li>Enquiry about adverse effects of corticosteroids, such as weight gain, dyspepsia, muscle weakness, skin thinning, and easy bruising — for more information, and details of the monitoring requirements for prednisolone, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li></ul></li><li><strong>Glucocorticoid treatment should be tapered when the person is in remission:</strong><ul><li>Initial doses of glucocorticoids should be continued until GCA symptoms and inflammatory markers resolve.</li><li>Once in clinical remission the specialist will determine a tapering schedule on a case by case basis.</li></ul></li><li><strong>Relapses are common when glucocorticoid dose is tapered:</strong><ul><li>Suspect relapse if the person develops recurrence of GCA symptoms or signs, ischaemic complications, or symptoms of polymyalgia rheumatica, particularly if there is a rise in erythrocyte sedimentation rate or C-reactive protein.</li><li>Be aware that relapse can occur with normal inflammatory markers.</li><li>If relapse is suspected, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/giant-cell-arteritis/management/management/#managing-relapse\">Managing relapse</a>.</li></ul></li><li><strong>Ensure that the person is provided with a blue steroid card, and discuss potential adverse effects of corticosteroids.</strong><ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>. In particular, advise the person:<ul><li>Not to stop taking prednisolone abruptly and to seek medical advice if they are experiencing problems.</li><li>That steroids may increase susceptibility to infections and possibly decrease vaccine efficacy — close contact with people who have chickenpox, shingles, or measles should be avoided if they do not have immunity to chickenpox or measles and they should seek urgent medical advice if exposed.</li><li>Live vaccines are contraindicated in people receiving high dose glucocorticoid therapy.</li></ul></li></ul></li><li><strong>Advise the person on:</strong><ul><li>Sources of information on the condition and support.</li><li>Symptoms that may indicate relapse, what they should do if they experience them, and who to contact — for more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/giant-cell-arteritis/management/management/#managing-relapse\">Managing relapse</a>.</li><li>Healthy diet, physical activity, and smoking cessation (where appropriate).</li></ul></li><li><strong>Long-term follow up may be arranged:</strong><ul><li>Local arrangements vary but long-term follow up to monitor for late complications such as aortic aneurysm may be arranged on a case by case basis by the person’s specialist.</li></ul></li></ul><!-- end field aae8ce3c-0e63-49e2-905b-e6a7c04613e9 --><!-- end item 94b46bfa-8ecd-4364-a68b-acdaa068a719 -->","subChapters":[{"id":"417ae6a8-5f3e-5248-9e96-82b8abbf5116","slug":"basis-for-recommendation-140","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e7bbedef-a5ba-47aa-863d-59818203b495 --><h4>Basis for recommendation</h4><!-- end field e7bbedef-a5ba-47aa-863d-59818203b495 -->","summary":null,"htmlStringContent":"<!-- begin item 140a3e55-92fc-4cc1-a7f0-10db5a6b7ba1 --><!-- begin field 19f06808-a1bc-4fd5-bb66-595919b47a25 --><p class=\"MsoNormal\">Recommendations are largely based on <em>The British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>], the European clinical guidelines <em>Management of giant cell arteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Bienvenu, 2016</a>], <em>Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Turesson, 2019</a>]</em>, <em>2018 Update of the EULAR recommendations for the management of large vessel vasculitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>], <em>European Headache Federation recommendations for neurologists managing giant cell arteritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mollan, 2020</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Prior, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Buttgereit, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>].</p><h5 class=\"MsoNormal\">Shared care</h5><ul><li class=\"MsoNormal\">The British Society of Rheumatology (BSR) guideline advises that for ongoing care using a shared care model, people with giant cell arteritis (GCA) should be seen by a clinician with appropriate expertise [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li><li>Within the shared care model the person and the GP should receive the information and support they need and have ready access to secondary care when needed.</li><li>The schedule of review described is taken from the BSR guideline — depending on the specific clinical situation this may vary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li><li>Details of what review should include are based on expert opinion in clinical guidance and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Turesson, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li></ul><h5 class=\"MsoNormal\">Consideration of prognostic factors and prevention of adverse effects</h5><ul><li class=\"MsoNormal\">The information is based on clinical guidelines and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Buttgereit, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>]. BSR recommends that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>]:<ul><li>Symptoms of and/or exposure to serious infections should be assessed in all patients starting glucocorticoids, considering the local prevalence of these infections — a chest radiograph and dipstick urinalysis should be performed.</li><li>Evaluation for hypertension and hyperglycaemia (blood glucose for acute changes and/or HbA1c to identify patients that might be at greater risk) takes place within the first 2 weeks of starting high dose glucocorticoids.</li><li>If there is a history or risk of glaucoma or ocular hypertension screening should be performed by a suitably trained eye professional.</li><li>Local or national guidance should be followed when considering the need for proton pump inhibitors with high dose glucocorticoid therapy — lower glucocorticoid doses may not always routinely need co-prescription of a proton pump inhibitor.</li></ul></li><li>The European Headache Federation recommends considering proton pump inhibitors for gastrointestinal protection in people at risk of gastrointestinal bleeding or dyspepsia and bone-sparing treatment, such as bisphosphonates, to people who are taking high doses of glucocorticoids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mollan, 2020</a>].</li><li>The recommendation to assess and treat osteoporotic fracture risk is consistent with UK guidelines from the National Institute for Health and Clinical Excellence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">NICE, 2017,</a>] and the National Osteoporosis Guideline Group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">NOGG, 2017</a>].<ul><li>More detail on the evidence influencing recommendations can be found in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>.</li></ul></li><li>The statement that adjunctive treatment such as methotrexate might be considered for GCA, in combination with a glucocorticoid taper, in patients at high risk of glucocorticoid toxicity or who relapse is a conditional recommendation from the BSR [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li><li>The BSR do not recommend the routine use of antiplatelet or anticoagulant agents for GCA (insufficient evidence) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].<ul><li>National and society guidelines for the secondary prevention of coronary and other atherosclerotic vascular disease should be followed.</li></ul></li></ul><h5 class=\"MsoNormal\">Treatment duration and tapering schedule</h5><ul><li class=\"MsoNormal\">The information on treatment duration and tapering is taken from the BSR clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>] that states that glucocorticoid dose should be tapered to zero over 12–18 months, providing there is no return of GCA symptoms, signs, or laboratory markers of inflammation. A more rapid dose reduction is appropriate for patients at high risk of glucocorticoid toxicity and/or those receiving concomitant glucocorticoid-sparing therapy.</li><li>Prednisolone tapering schedules are likely to vary locally and should be determined on a case by case basis.</li></ul><h5 class=\"MsoNormal\">Relapse</h5><ul><li class=\"MsoNormal\">Recommendations on when to suspect relapse are based on expert opinion in clinical guidelines and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li><li>Relapse rates of 34–75% in patients with GCA treated with glucocorticoid therapy have been reported in large observational cohort studies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>].</li></ul><h5 class=\"MsoNormal\">Advice</h5><ul><li class=\"MsoNormal\">Recommendations on advice and information are based on the BSR clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>], reflecting the need to identify relapse and prevent corticosteroid adverse effects.<ul><li>GCA is a chronic medical condition that can be life changing — patient information on the condition and access to support networks should be offered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>].</li></ul></li><li>Information on increased susceptibility to infection and vaccination is based on the BSR guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>] and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">BNF, 2020</a>].<ul><li>Prolonged courses of corticosteroids increase susceptibility to infection. Unless people taking long-term corticosteroids have had chickenpox, they should be regarded as being at risk of severe chickenpox. Manifestations of fulminant illness include pneumonia, hepatitis, and disseminated intravascular coagulation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">BNF, 2020</a>].</li><li>Patients without a history of chicken pox should be advised to avoid close contact with people who have chickenpox or shingles and to seek urgent medical advice if they have been exposed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li><li>Live vaccines are contraindicated in patients receiving high dose glucocorticoid therapy (greater than 20 mg prednisolone daily for 2 weeks or more) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li></ul></li></ul><h5 class=\"MsoNormal\">Long-term monitoring</h5><ul><li class=\"MsoNormal\">Information on long-term follow up to identify late complications such as aortic aneurysm is based on clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Bienvenu, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Kermani, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Koster, 2018</a>].</li><li class=\"MsoNormal\">The BSR recognizes that people with GCA are at increased risk of developing aortic aneurysms, however, there is uncertain cost-effectiveness in carrying out routine aortic imaging for all people with GCA and the optimal method and timing of imaging is still unclear — clinical judgement is advised when selecting people for aortic imaging [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li></ul><!-- end field 19f06808-a1bc-4fd5-bb66-595919b47a25 --><!-- end item 140a3e55-92fc-4cc1-a7f0-10db5a6b7ba1 -->","subChapters":[]}]},{"id":"4dd85c16-cb8b-57e4-964a-f239409926a1","slug":"managing-relapse","fullItemName":"Managing relapse","depth":3,"htmlHeader":"<!-- begin field ba4875ec-902e-49b1-a148-7c7bd0e5ed92 --><h3>How should I manage relapse?</h3><!-- end field ba4875ec-902e-49b1-a148-7c7bd0e5ed92 -->","summary":null,"htmlStringContent":"<!-- begin item 8a0e054d-97d0-4696-a708-11c953245827 --><!-- begin field 9a9b99da-fb34-4ca6-bcec-0e376e0a0e1d --><ul><li class=\"MsoNormal\"><strong>Relapse of giant cell arteritis (GCA) is defined as the return of <a class=\"topic-reference internal-reference\" href=\"/topics/giant-cell-arteritis/diagnosis/suspecting-giant-cell-arteritis/\">signs or symptoms</a> not attributable to another cause, with or without changes in inflammatory markers (erythrocyte sedimentation rate or C-reactive protein).</strong><ul><li>An isolated elevation of inflammatory markers in the absence of clinical symptoms should not routinely result in an increase in corticosteroid dose.</li><li>Suspect relapse if the person develops recurrence of GCA symptoms or signs, ischaemic complications, or symptoms of polymyalgia rheumatica.</li></ul></li><li><strong>If the person has new-onset visual disturbance:</strong><ul><li>Refer for urgent (same day) assessment by an ophthalmologist — high dose steroids are required and adjunctive treatment (for example with methotrexate or a biologic) may be considered.</li></ul></li><li><strong>If the person has:</strong><ul><li><strong>Possible GCA relapse with ischaemic symptoms </strong>such as jaw or tongue claudication or other features of ischaemia:<ul><li>Discuss management urgently with the person’s specialist.</li><li>Ischaemic symptoms such as jaw claudication are classified as a major relapse and require high doses of steroids (similar to new-onset disease) with or without a glucocorticoid-sparing agent.</li></ul></li><li><strong>Possible GCA relapse without ischaemic symptoms</strong> such as recurrence of headache:<ul><li>Discuss increase in steroid dose with the person’s specialist.</li><li>In general for minor relapses an increase in dose of steroids to at least the last effective dose may be adequate.</li></ul></li><li><strong>Possible GCA related inflammation of the aorta and/or its proximal branches</strong> (which may present with symptoms such as weight loss, fever, night sweats, anaemia, persistently raised inflammatory markers, polymyalgia rheumatica symptoms, limb claudication, abdominal or back pain):<ul><li>Discuss urgently with the person's specialist.</li><li>Vascular imaging, an increase in prednisolone, and/or addition of glucocorticoid sparing treatment will be considered.</li></ul></li></ul></li><li><strong>If the person has recurrent relapses</strong> — initiation or modification of adjunctive therapy (such as methotrexate or a biologic) will be considered by the person’s specialist.</li></ul><!-- end field 9a9b99da-fb34-4ca6-bcec-0e376e0a0e1d --><!-- end item 8a0e054d-97d0-4696-a708-11c953245827 -->","subChapters":[{"id":"3a4faf3e-84a0-5fe1-a130-441a7970180a","slug":"basis-for-recommendation-859","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8f1093f4-0bcb-4446-9a56-813549cb72b6 --><h4>Basis for recommendation</h4><!-- end field 8f1093f4-0bcb-4446-9a56-813549cb72b6 -->","summary":null,"htmlStringContent":"<!-- begin item 8593cdde-c784-4076-9bc9-ac95fecdf587 --><!-- begin field 0a54a890-0492-4697-8fe8-b8978cacae1d --><p class=\"MsoNormal\">These recommendations are based on the clinical guidelines <em>Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Turesson, 2019</a>], the <em>British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>], the <em>2018 Update of the EULAR recommendations for the management of large vessel vasculit</em>is [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>], feedback from CKS expert reviewers, and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Bienvenu, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>].</p><ul><li class=\"MsoNormal\">Relapses are common and can occur if corticosteroid treatment is reduced or withdrawn too quickly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>].</li><li class=\"MsoNormal\">Relapses are typically, but not always, associated with an increase in inflammatory markers (erythrocyte sedimentation rate [ESR] or C-reactive protein [CRP]).<ul><li>Clinical guidance from EULAR states that a rise of ESR or CRP should not automatically lead to immediate increase in therapy and that other causes (such as infection or neoplasia) need to be considered. Imaging may be considered by the person's specialist if they have either repeat measurements confirming raised inflammatory markers without evidence of another cause or less specific symptoms (such as diffuse headache) without raised inflammatory markers [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>].</li></ul></li><li>Major relapses should be treated like new-onset disease with high dose glucocorticoids as they increase the risk of ischaemic organ damage and/or progressive vascular inflammation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>].</li><li>Minor relapses can be appropriately treated with an increase of the glucocorticoid dose either to the last effective dose or to 5–15 mg above this dose [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Bienvenu, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hellmich, 2020</a>].</li><li>Adjunctive treatment (for example with methotrexate or tocilizumab) may be considered, in combination with a glucocorticoid taper, in people who relapse or are at high risk of glucocorticoid toxicity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>].</li></ul><!-- end field 0a54a890-0492-4697-8fe8-b8978cacae1d --><!-- end item 8593cdde-c784-4076-9bc9-ac95fecdf587 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}